Related Experiment Videos
Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis
G W Kaatz1, S M Seo, S L Barriere
1Department of Internal Medicine, Wayne State University School of Medicine, Detroit, Michigan.
Abstract:
The efficacy of fleroxacin versus that of vancomycin was assessed by using the rabbit model of methicillin-resistant Staphylococcus aureus endocarditis. Animals were treated with fleroxacin (30 mg/kg of body weight every 8 h) or vancomycin (17.5 mg/kg every 6 h) for 4 days. These antimicrobial agents were equally effective in clearing bacteremia, reducing bacterial counts in vegetations and tissues, and curing endocarditis. However, resistance to fleroxacin at fivefold the MIC arose in the test strain of S. aureus in 8% of animals that received the drug. We conclude that fleroxacin is as efficacious as vancomycin in this model of a serious systemic S. aureus infection, but modest resistance to fleroxacin may develop during therapy.
Insights
Fleroxacin and vancomycin showed equal efficacy in treating methicillin-resistant Staphylococcus aureus endocarditis in rabbits. However, some rabbits treated with fleroxacin developed resistance to the antibiotic.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) causes severe infections like endocarditis.
- Vancomycin is a standard treatment, but resistance is a growing concern.
- Novel antibiotics are needed to combat resistant bacterial strains.
Purpose of the Study:
- To compare the efficacy of fleroxacin and vancomycin in a rabbit model of MRSA endocarditis.
- To evaluate the development of antibiotic resistance during treatment.
Main Methods:
- Rabbits with induced MRSA endocarditis were treated with either fleroxacin or vancomycin for 4 days.
- Efficacy was assessed by measuring bacteremia, vegetation bacterial counts, tissue burden, and cure rates.
- Development of resistance was monitored by determining the minimum inhibitory concentration (MIC).
Main Results:
- Both fleroxacin and vancomycin were equally effective in clearing bacteremia, reducing bacterial load in vegetations and tissues, and curing endocarditis.
- Fleroxacin resistance (fivefold increase in MIC) developed in 8% of rabbits treated with the drug.
- No significant difference in cure rates was observed between the two treatment groups.
Conclusions:
- Fleroxacin demonstrates comparable efficacy to vancomycin for MRSA endocarditis in this animal model.
- The potential for modest fleroxacin resistance development during therapy warrants consideration.
- Fleroxacin may be a viable alternative, but resistance monitoring is crucial.